Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Rating of “Moderate Buy” by Brokerages

Amicus Therapeutics, Inc. (NASDAQ:FOLD) has earned an average recommendation of “Moderate Buy” from the nine research firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $17.25.

A number of analysts have commented on the stock. JPMorgan Chase & Co. lowered their target price on shares of Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a report on Friday, August 16th. Wells Fargo & Company initiated coverage on Amicus Therapeutics in a report on Thursday, May 30th. They issued an “overweight” rating and a $18.00 price objective for the company. Jefferies Financial Group began coverage on Amicus Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $18.00 target price on the stock. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research note on Friday, August 9th.

Insider Buying and Selling

In related news, CEO Bradley L. Campbell sold 6,100 shares of the company’s stock in a transaction on Friday, July 5th. The shares were sold at an average price of $10.00, for a total value of $61,000.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $8,866,540. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $11.71, for a total value of $87,825.00. Following the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at $10,382,718.34. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bradley L. Campbell sold 6,100 shares of the firm’s stock in a transaction on Friday, July 5th. The shares were sold at an average price of $10.00, for a total transaction of $61,000.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $8,866,540. The disclosure for this sale can be found here. Insiders have sold a total of 21,100 shares of company stock worth $226,375 over the last ninety days. Company insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On Amicus Therapeutics

A number of large investors have recently modified their holdings of FOLD. Headlands Technologies LLC bought a new stake in Amicus Therapeutics during the second quarter worth about $89,000. Sage Capital Advisors llc bought a new position in shares of Amicus Therapeutics in the second quarter valued at $103,000. Sanctuary Advisors LLC acquired a new position in Amicus Therapeutics during the second quarter worth $138,000. EntryPoint Capital LLC raised its position in Amicus Therapeutics by 278.8% during the first quarter. EntryPoint Capital LLC now owns 13,218 shares of the biopharmaceutical company’s stock worth $156,000 after acquiring an additional 9,729 shares in the last quarter. Finally, Old Well Partners LLC acquired a new stake in Amicus Therapeutics in the fourth quarter valued at $180,000.

Amicus Therapeutics Trading Down 2.6 %

FOLD stock opened at $10.91 on Thursday. The company has a quick ratio of 2.26, a current ratio of 2.75 and a debt-to-equity ratio of 2.93. Amicus Therapeutics has a twelve month low of $9.02 and a twelve month high of $14.57. The company has a market cap of $3.23 billion, a P/E ratio of -22.78 and a beta of 0.69. The business has a fifty day moving average of $11.00 and a 200-day moving average of $10.74.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.05). Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The company had revenue of $126.67 million for the quarter, compared to the consensus estimate of $121.21 million. During the same period in the prior year, the company posted ($0.15) EPS. The company’s revenue was up 34.0% compared to the same quarter last year. As a group, equities research analysts expect that Amicus Therapeutics will post -0.08 EPS for the current year.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.